share_log

6-K: Supernova Phase Iii Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing Covid-19 in Immunocompromised Patient Population

SEC announcement ·  May 16 06:46
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more